[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Founded in July 2019 by Prof. Dr. Jens Schwamborn and Dr. Javier Jarazo, the Luxembourgish biotech company OrganoTherapeutics S.a.r.l. (OT) makes use of a proprietary human-specific 3D in vitro model, the so-called midbrain organoids, for the discovery and development of effective drug candidates, which target neurodegeneration in Parkinson`s disease (PD) patients. The business strategy of OT is based on three pillars: I) usage of the midbrain organoids for own drug development, II) usage of midbrain organoids for joint drug development campaigns with other biotech & pharma companies and II) selling of midbrain organoids as product for R&D.
Prof. Dr.